Noubar Afeyan

CIK: 0001222012

Transaction Breakdown

Open Market Buys (P)3 (18.8%)

High conviction signal

Open Market Sales (S)2 (12.5%)

Position reduction

Option Exercises (M)2 (12.5%)

Derivative conversions

Awards (A)4 (25.0%)

Compensation grants

Other (G, F, J, C, D, …)5 (31.3%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

MRNA

Moderna, Inc.

Director

GENB

Generate Biomedicines, Inc.

Director10% Owner

Discretionary Trading P&L

Holdings

Transaction History (16 total)

MRNA
Moderna, Inc.
May 21, 2026
Exercise(M)
Indirect
9.3K shares at avg. $19.15$177K
MRNA
Moderna, Inc.
May 21, 2026
Sale(S)
Indirect
9.3K shares at avg. $46.84$434K
MRNA
Moderna, Inc.
May 6, 2026
Award(A)
Stock Option (Right to Buy)
Direct
12.9K shares-
GENB
Generate Biomedicines, Inc.
Mar 2, 2026
Conversion(C)
Indirect
12.7M shares-
GENB
Generate Biomedicines, Inc.
Mar 2, 2026
Conversion(C)
Indirect
2.8M shares-
GENB
Generate Biomedicines, Inc.
Mar 2, 2026
Purchase(P)
Indirect
1.6M shares at avg. $16.00$25.0M
GENB
Generate Biomedicines, Inc.
Mar 2, 2026
Purchase(P)
Indirect
1.6M shares at avg. $16.00$25.0M
GENB
Generate Biomedicines, Inc.
Mar 2, 2026
Purchase(P)
Indirect
1.6M shares at avg. $16.00$25.0M
GENB
Generate Biomedicines, Inc.
Mar 2, 2026
Conversion(C)
Indirect
987.5K shares-
GENB
Generate Biomedicines, Inc.
Mar 2, 2026
Conversion(C)
Indirect
13.7M shares-
GENB
Generate Biomedicines, Inc.
Mar 2, 2026
Conversion(C)
Indirect
2.8M shares-
GENB
Generate Biomedicines, Inc.
Feb 26, 2026
Award(A)
Stock Option (Right to Buy)
Direct
29.6K shares-
GENB
Generate Biomedicines, Inc.
Feb 26, 2026
Award(A)
Stock Option (Right to Buy)
Direct
29.6K shares-
MRNA
Moderna, Inc.
Dec 11, 2025
Sale(S)
Indirect
23.9K shares at avg. $29.48$703K
MRNA
Moderna, Inc.
Dec 11, 2025
Exercise(M)
Indirect
23.9K shares at avg. $10.90$260K
MRNA
Moderna, Inc.
Apr 30, 2025
Award(A)
Stock Option (Right to Buy)
Direct
25.5K shares-

		Type	Shares	Price		Ownership
May 21, 2026	MRNA Moderna, Inc.	Exercise(M)	9,263	$19.15	$177,386	Indirect
May 21, 2026	MRNA Moderna, Inc.	Sale(S)	9,263	$46.84	$433,879	Indirect
May 6, 2026	MRNA Moderna, Inc.	Award(A) Stock Option (Right to Buy)	12,908	-	-	Direct
Mar 2, 2026	GENB Generate Biomedicines, Inc.	Conversion(C)	12,723,940	-	$0	Indirect
Mar 2, 2026	GENB Generate Biomedicines, Inc.	Conversion(C)	2,777,752	-	$0	Indirect
Mar 2, 2026	GENB Generate Biomedicines, Inc.	Purchase(P)	1,562,500	$16.00	$25,000,000	Indirect
Mar 2, 2026	GENB Generate Biomedicines, Inc.	Purchase(P)	1,562,500	$16.00	$25,000,000	Indirect
Mar 2, 2026	GENB Generate Biomedicines, Inc.	Purchase(P)	1,562,500	$16.00	$25,000,000	Indirect
Mar 2, 2026	GENB Generate Biomedicines, Inc.	Conversion(C)	987,491	-	$0	Indirect
Mar 2, 2026	GENB Generate Biomedicines, Inc.	Conversion(C)	13,702,224	-	$0	Indirect
Mar 2, 2026	GENB Generate Biomedicines, Inc.	Conversion(C)	2,777,752	-	$0	Indirect
Feb 26, 2026	GENB Generate Biomedicines, Inc.	Award(A) Stock Option (Right to Buy)	29,561	-	-	Direct
Feb 26, 2026	GENB Generate Biomedicines, Inc.	Award(A) Stock Option (Right to Buy)	29,561	-	-	Direct
Dec 11, 2025	MRNA Moderna, Inc.	Sale(S)	23,853	$29.48	$703,306	Indirect
Dec 11, 2025	MRNA Moderna, Inc.	Exercise(M)	23,853	$10.90	$259,998	Indirect
Apr 30, 2025	MRNA Moderna, Inc.	Award(A) Stock Option (Right to Buy)	25,512	-	-	Direct

1-16 of 16 transactions

About AFEYAN NOUBAR

AFEYAN NOUBAR (SEC CIK 0001222012) files insider reports with the SEC as Director of Moderna, Inc. (MRNA) and Director of Generate Biomedicines, Inc. (GENB).

Signal8 holds 8 ownership filings by AFEYAN NOUBAR (2 Form 3, 6 Form 4), filed between May 1, 2025 and May 22, 2026. Those filings report 16 transactions, from Apr 30, 2025 to May 21, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on AFEYAN NOUBAR's filings is in CAMBRIDGE, MA.

Recent filings by AFEYAN NOUBAR

May 21, 2026: Option exercise of MRNA shares (Form 4, code M).
May 21, 2026: Open-market sale of MRNA shares (Form 4, code S).
May 6, 2026: Grant or award of MRNA derivative securities (Form 4, code A).
Mar 2, 2026: Conversions of GENB shares (2 lines, Form 4, code C).
Mar 2, 2026: Open-market purchases of GENB shares (3 lines, Form 4, code P).

Other insiders filing for Moderna, Inc. (MRNA)

Hoge Stephen, President
Mock James M, Chief Financial Officer
Andres Juan, Chief Operating Officer
Klinger Shannon Thyme, Chief Legal Officer
Bancel Stephane, Chief Executive Officer
McDonnell Michael R., Director

How to read Form 4 transaction codes